Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer

25 Mar 2017

Abstract excerpt

// Jung-Min Lee 1 , John L. Hays 2 , Victoria L. Chiou 1 , Christina M. Annunziata 1 , Elizabeth M. Swisher 3 , Maria I. Harrell 3 , Minshu Yu 1 , Nicolas Gordon 1 , Tristan M. Sissung 4 , Jiuping Ji 5 , William D. Figg 4 , Lori Minasian 1 , Stanley Lipkowitz 1 , Bradford J. Wood 6 , James Doroshow 7 and Elise C. Kohn 1 1 Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to PARP inhibition in cancer therapy
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29108297
DOI: 10.18632/oncotarget.16577

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerPMID 29108297Read ↗

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerSemantic proximity Read ↗

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.Semantic proximity Read ↗

Targeted and cytotoxic inhibitors used in the treatment of breast cancerSemantic proximity Read ↗

Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesSemantic proximity Read ↗

Olaparib for the treatment of breast cancer.Semantic proximity Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

Recent Advances in the Treatment of Breast CancerSemantic proximity Read ↗

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 MutationSemantic proximity Read ↗

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read ↗

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).Semantic proximity Read ↗

BRCA testing and Japanese original testing criteria for hereditary breast and ovarian cancer covered by public health insuranceSemantic proximity Read ↗

Targeting basal-like breast cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.